Literature DB >> 9580614

Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs.

L Sen1, G Cui, Y Sakaguchi, B N Singh.   

Abstract

MS-551 is a newly synthesized, nonspecific K+ channel blocker. To elucidate its electrophysiological and potential proarrhythmic effects relative to those of dl-sotalol in vivo, serial changes in ECGs, endocardial and epicardial monophasic action potential durations, and left and right ventricular pressures were measured simultaneously in pentobarbital-anesthetized open-chest dogs. Complete heart block was produced by the injection of 37% formaldehyde into the atrioventricular node. Intravenous administration of MS-551 produced prolongation of action potential duration at 90% repolarization time (APD90) immediately after the beginning of infusion and reached plateau at 10 min. MS-551 (1 mg/kg) caused 73 +/- 8% increase in APD90 and 28 +/- 5% increase in QTc at basic cycle length of 700 msec. The maximal prolongation of APD90 induced by 1 mg/kg MS-551 was 39% greater than that by the same dose of sotalol (P < .01). The dose-response curve of prolongation of ventricular effective refractory period produced by MS-551 was shifted significantly to the left compared with that induced by sotalol. The EC50 was 0.5 +/- 0.1 mg/kg and 1.2 +/- 0.2 mg/kg for MS-551 and sotalol, respectively (P < .05). When 0.5 mg/kg MS-551 doses were used, no ventricular arrhythmia was induced by stimulation at 200-msec basic cycle length. When 1.5 mg/kg sotalol was administered, 5 of 15 developed torsade de pointes, 2 of 15 developed ventricular fibrillation and 5 of 15 developed sustained ventricular tachycardia. The idioventricular rates and left ventricular pressures were reduced significantly by sotalol, not by MS-551. In conclusion, MS-551 is a potent class III antiarrhythmic agent that selectively prolongs repolarization in the ventricular myocardium and appears to be devoid of autonomic effects. Dose for dose, it is more potent in prolonging the APD90 and the right ventricular effective refractory period possibly with a lower tendency for the development of proarrhythmia in a canine heart-block model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580614

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias.

Authors:  Ioannis N Pantazopoulos; Georgios T Troupis; Charalampos N Pantazopoulos; Theodoros T Xanthos
Journal:  World J Cardiol       Date:  2011-06-26

2.  Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation.

Authors:  Nobuya Harayama; Shun-ichi Nihei; Keiji Nagata; Yasuki Isa; Kei Goto; Keiji Aibara; Masayuki Kamochi; Takeyoshi Sata
Journal:  J Anesth       Date:  2014-01-05       Impact factor: 2.078

Review 3.  Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation.

Authors:  Takashi Tagami; Hideo Yasunaga; Hiroyuki Yokota
Journal:  Crit Care       Date:  2017-03-21       Impact factor: 9.097

4.  Electrophysiologic effects of the IK1 inhibitor PA-6 are modulated by extracellular potassium in isolated guinea pig hearts.

Authors:  Gregory S Hoeker; Mark A Skarsfeldt; Thomas Jespersen; Steven Poelzing
Journal:  Physiol Rep       Date:  2017-01-13

5.  Pharmacological inhibition of IK1 by PA-6 in isolated rat hearts affects ventricular repolarization and refractoriness.

Authors:  Mark A Skarsfeldt; Helena Carstensen; Lasse Skibsbye; Chuyi Tang; Rikke Buhl; Bo H Bentzen; Thomas Jespersen
Journal:  Physiol Rep       Date:  2016-04

6.  Negative lusitropic property of nifekalant identified using ventricular pressure-volume loop analyses in anesthetized monkeys.

Authors:  Tomomichi Ishizaka; Yu Yoshimatsu; Yu Maeda; Katsuyoshi Chiba; Kazuhiko Mori
Journal:  Exp Anim       Date:  2018-10-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.